当前位置: 首页 > 详情页

Tert-butylhydroquinone prevents neuroinflammation and relieves depression via regulation of NLRP3 signaling in mice.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China [2]Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China [3]Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China [4]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: Tert-butylhydroquinone Depression Neuroinflammation NLRP3 Lipopolysaccharide

摘要:
Depression is a common psychiatric disorder, which seriously affects people's health and quality of life. Current treatments, which mainly focus on neurotransmitter levels, are not effective in many patients. Recent studies have shown that neuroinflammation has certain correlation with the pathogenesis of depression. Tert-butylhydroquinone (TBHQ) is an antioxidant with an anti-inflammatory effect. The present study evaluated the effects of TBHQ on the improvement of depression-like behaviors induced by lipopolysaccharide (LPS) in mice and its possible mechanism. Behavioral test results showed that TBHQ treatment could significantly improve the depression-like behaviors of mice. Western blot results showed that TBHQ treatment inhibited the protein expression of NLRP3, Caspase-1, IL-1β, and IL-18, which induced by LPS. Immunofluorescence staining results showed that TBHQ treatment inhibited the activation of microglia induced by LPS. These results suggested that, by inhibiting LPS-induced neuroinflammation and microglia activation, TBHQ could effectively improve LPS-induced inflammation-related depression-like behavior through modulating the NLRP3 signaling pathway.Copyright © 2022 Elsevier B.V. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 药学
JCR分区:
出版当年[2020]版:
Q2 IMMUNOLOGY Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
通讯作者:
通讯机构: [1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China [2]Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China [3]Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China [4]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China [*1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China [*2]Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院